Position in TNGX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$2,195,763
+$188,079 QoQ
Shares Held
104,960
-53.7% QoQ
Ownership
0.073%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in TNGX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rafferty Asset Management, LLC holds $408,627,656 across 136 Biotechnology names. TNGX ranks #68 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
54,572 | $24,368,580 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
29,589 | $22,861,644 | |
| 3 | INSM |
INSMED Inc
|
116,069 | $18,979,602 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
50,553 | $16,726,471 | |
| 5 | APLS |
Apellis Pharmaceuticals, Inc.
|
180,471 | $7,260,348 | |
| 6 | MRNA |
Moderna, Inc.
|
114,194 | $5,801,055 | |
| 7 | INCY |
Incyte Corp
|
60,565 | $5,700,377 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
10,452 | $5,471,308 |
All Filings in TNGX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,195,763 | 104,960 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $2,007,684 | 226,601 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $1,220,654 | 145,316 | Shares | Sole | 2025-11-12 | |
| 2024-09-30 | $792,753 | 102,955 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $625,387 | 72,889 | Shares | Sole | 2024-08-13 | |
| 2024-03-31 | $1,746,950 | 220,019 | Shares | Sole | 2024-05-13 | |
| No filing history on record for this holder in this stock. | ||||||